- Home
- WFG vs JAZZ Comparison
WFG vs JAZZ Comparison
Compare WFG & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFG
- JAZZ
- Stock Information
- Founded
- WFG 1955
- JAZZ 2003
- Country
- WFG Canada
- JAZZ Ireland
- Employees
- WFG N/A
- JAZZ N/A
- Industry
- WFG
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- WFG
- JAZZ Health Care
- Exchange
- WFG Nasdaq
- JAZZ Nasdaq
- Market Cap
- WFG 7.8B
- JAZZ 6.5B
- IPO Year
- WFG N/A
- JAZZ 2007
- Fundamental
- Price
- WFG $91.87
- JAZZ $121.65
- Analyst Decision
- WFG Buy
- JAZZ Buy
- Analyst Count
- WFG 4
- JAZZ 14
- Target Price
- WFG $106.25
- JAZZ $173.57
- AVG Volume (30 Days)
- WFG 161.0K
- JAZZ 653.4K
- Earning Date
- WFG 10-23-2024
- JAZZ 11-06-2024
- Dividend Yield
- WFG 1.39%
- JAZZ N/A
- EPS Growth
- WFG N/A
- JAZZ 458.10
- EPS
- WFG N/A
- JAZZ 7.04
- Revenue
- WFG $6,283,000,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- WFG N/A
- JAZZ $7.43
- Revenue Next Year
- WFG $6.67
- JAZZ $6.39
- P/E Ratio
- WFG N/A
- JAZZ $17.29
- Revenue Growth
- WFG N/A
- JAZZ 5.23
- 52 Week Low
- WFG $72.35
- JAZZ $99.06
- 52 Week High
- WFG $102.40
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- WFG 44.16
- JAZZ 59.73
- Support Level
- WFG $90.73
- JAZZ $108.74
- Resistance Level
- WFG $93.52
- JAZZ $128.99
- Average True Range (ATR)
- WFG 2.63
- JAZZ 2.99
- MACD
- WFG -0.15
- JAZZ 1.14
- Stochastic Oscillator
- WFG 36.36
- JAZZ 63.75
About WFG West Fraser Timber Co. Ltd Common stock
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is now one of the largest oriented strand board, or OSB, producers in the world.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.